Related Experiment Video

Updated: Mar 6, 2026

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

11.0K

Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review

A Jameera Begam1, S Jubie1, M J Nanjan2

  • 1Department of Pharmaceutical Chemistry, JSS College of Pharmacy, Udhagamandalam, India; A Constituent College of JSS University, Mysore, India.

Bioorganic Chemistry
|March 10, 2017
PubMed

Insights

Newer breast cancer therapies are needed as Tamoxifen is the sole option for estrogen-related tumors. This review explores selective estrogen receptor modulators and antagonists for improved breast cancer treatment.

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Estrogen's tissue-selective actions are crucial for breast cancer therapeutics.
  • Estrogens, both endogenous and exogenous, play a role in breast cancer development.
  • Tamoxifen has been the primary treatment for estrogen receptor-positive breast tumors for over 30 years.

Purpose of the Study:

  • To review novel therapeutic candidates for breast cancer.
  • To focus on selective estrogen receptor modulators and estrogen antagonists.
  • To provide an overview of estrogen receptors, signaling, and their role in breast carcinogenesis.

Main Methods:

  • Literature review of selective estrogen receptor modulators.
  • Analysis of estrogen antagonists, including sulfatase and aromatase inhibitors.
  • Critical overview of estrogen receptor structure and signaling pathways.

Main Results:

  • Identified selective estrogen receptor modulators and antagonists as key therapeutic targets.
  • Highlighted the involvement of estrogen receptor signaling in breast cancer.
  • Discussed the limitations of current therapies and the need for novel agents.

Conclusions:

  • Selective estrogen receptor modulators and antagonists offer promising avenues for breast cancer therapy.
  • Understanding estrogen receptor signaling is vital for developing effective breast cancer treatments.
  • There is a significant need for novel therapeutic strategies beyond Tamoxifen for estrogen-related breast cancers.
Keywords:
AromataseBreast cancerEstrogen receptorSulfataseTamoxifen

More Related Videos

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.7K
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

13.0K

Related Concept Videos

Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.4K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
5.3K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
519
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
4.2K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.8K